{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:07:28Z","timestamp":1790701648842,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jpet.2026.105002","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:50:51Z","timestamp":1785772251000},"page":"105002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic mechanistic dominance in fentanyl and polysubstance overdose: Implications for next-generation reversal"],"prefix":"10.1016","volume":"393","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-0529","authenticated-orcid":false,"given":"Michael","family":"Voronkov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Milevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2407-6629","authenticated-orcid":false,"given":"John","family":"Abernethy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib2","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0035-23.2023","article-title":"Fentanyl-induced respiratory depression and locomotor hyperactivity are mediated by \u03bc-opioid receptors expressed in somatostatin-negative neurons","volume":"10","author":"Furdui","year":"2023","journal-title":"eNeuro"},{"key":"10.1016\/j.jpet.2026.105002_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1277248","article-title":"Comparison of the effects of fentanyls and other \u03bc opioid receptor agonists on the electrical activity of respiratory muscles in the rat","volume":"14","author":"Cavallo","year":"2023","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2026.105002_bib4","article-title":"Case report of very-low-dose fentanyl causing fentanyl-induced chest wall rigidity","volume":"15","author":"Zoorob","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1113\/JP289107","article-title":"Fentanyl blockade of K(+) channels contributes to wooden chest syndrome","volume":"604","author":"Wei","year":"2026","journal-title":"J Physiol"},{"issue":"16","key":"10.1016\/j.jpet.2026.105002_bib6","doi-asserted-by":"crossref","first-page":"282","DOI":"10.15585\/mmwr.mm7416a2","article-title":"Trends in suspected fentanyl-involved nonfatal overdose emergency department visits, by age group, sex, and race and ethnicity\u2014United States, October 2020\u2013March 2024","volume":"74","author":"Pickens","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"10.1016\/j.jpet.2026.105002_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/JAN.0000000000000230","article-title":"Naloxone effectiveness: a systematic review","volume":"29","author":"Chimbar","year":"2018","journal-title":"J Addict Nurs"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234683","article-title":"Higher naloxone dosing in a quantitative systems pharmacology model that predicts naloxone-fentanyl competition at the opioid mu receptor level","volume":"15","author":"Moss","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.51839","article-title":"Intranasal naloxone repeat dosing strategies and fentanyl overdose: a simulation-based randomized clinical trial","volume":"7","author":"Strauss","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s41181-025-00394-z","article-title":"[11C]Fentanyl: radiosynthesis and preclinical PET imaging for its pharmacokinetics","volume":"10","author":"Kim","year":"2025","journal-title":"JNMMI Radiopharm Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1080\/08897077.2021.2010252","article-title":"The need for multiple naloxone administrations for opioid overdose reversals: A review of the literature","volume":"43","author":"Abdelal","year":"2022","journal-title":"Subst Abus"},{"issue":"5","key":"10.1016\/j.jpet.2026.105002_bib12","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jemermed.2011.03.011","article-title":"Recurrent respiratory depression associated with fentanyl transdermal patch gel reservoir ingestion","volume":"42","author":"D\u2019Orazio","year":"2012","journal-title":"J Emerg Med"},{"issue":"11","key":"10.1016\/j.jpet.2026.105002_bib13","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.3390\/ph18111634","article-title":"Is fentanyl rebound an intrinsic feature of naloxone reversal?","volume":"18","author":"Voronkov","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"10.1016\/j.jpet.2026.105002_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40262-024-01355-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of naloxone","volume":"63","author":"Saari","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jpet.2026.105002_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.neubiorev.2018.12.005","article-title":"Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment","volume":"106","author":"Comer","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.jpet.2026.105002_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110512","article-title":"Pharmacology of newly identified nitazene variants reveals structural determinants of affinity, potency, selectivity for mu opioid receptors","volume":"276","author":"Kozell","year":"2025","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib17","first-page":"R1867","article-title":"Central alpha2-receptor mechanisms contribute to enhanced renal responses during ketamine-xylazine anesthesia","volume":"275","author":"Cabral","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.jpet.2026.105002_bib18","first-page":"49","article-title":"Pharmacokinetics of medetomidine","volume":"85","author":"Salonen","year":"1989","journal-title":"Acta Vet Scand Suppl"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2165\/00003088-197803010-00005","article-title":"Clinical pharmacokinetics of diazepam","volume":"3","author":"Mandelli","year":"1978","journal-title":"Clin Pharmacokinet"},{"issue":"15","key":"10.1016\/j.jpet.2026.105002_bib20","first-page":"7337","article-title":"Pharmacology and toxicology of xylazine: quid novum?","volume":"27","author":"Malaca","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.jpet.2026.105002_bib21","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1080\/15563650.2022.2063135","article-title":"Xylazine poisoning: a systematic review","volume":"60","author":"Ball","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"issue":"21","key":"10.1016\/j.jpet.2026.105002_bib22","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1021\/acschemneuro.4c00583","article-title":"Classics in chemical neuroscience: medetomidine","volume":"15","author":"de Andrade Horn","year":"2024","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"10.1016\/j.jpet.2026.105002_bib23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/ADM.0000000000001592","article-title":"The shifting landscape of a fentanyl adulterant: moving from xylazine to medetomidine","volume":"20","author":"Huo","year":"2026","journal-title":"J Addict Med"},{"issue":"5","key":"10.1016\/j.jpet.2026.105002_bib24","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/ajad.70030","article-title":"Rise of illicit medetomidine use: a worrisome trend","volume":"34","author":"Sood","year":"2025","journal-title":"Am J Addict"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib25","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.123.002052","article-title":"Pharmacologic characterization of substituted nitazenes at \u03bc, \u03ba, and \u03b4 opioid receptors suggests high potential for toxicity","volume":"389","author":"Kozell","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/15563650.2025.2504133","article-title":"Nitazenes: review of comparative pharmacology and antagonist action","volume":"63","author":"Stangeland","year":"2025","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib27","first-page":"54","article-title":"Adulterants in drugs of abuse: a recent focus of a changing phenomenon","volume":"173","author":"Di Trana","year":"2022","journal-title":"Clin Ter"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/FTD.0000000000000851","article-title":"Levamisole-a toxic adulterant in illicit drug preparations: a review","volume":"43","author":"Midthun","year":"2021","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib29","doi-asserted-by":"crossref","first-page":"542","DOI":"10.21037\/apm.2019.12.09","article-title":"Combining opioids and benzodiazepines: effects on mortality and severe adverse respiratory events","volume":"9","author":"Boon","year":"2020","journal-title":"Ann Palliat Med"},{"issue":"3","key":"10.1016\/j.jpet.2026.105002_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/ALN.0000000000001505","article-title":"Influence of ethanol on oxycodone-induced respiratory depression: a dose-escalating study in young and elderly individuals","volume":"126","author":"van der Schrier","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jpet.2026.105002_bib31","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.2147\/JPR.S144963","article-title":"Risk of respiratory depression with opioids and concomitant gabapentinoids","volume":"10","author":"Savelloni","year":"2017","journal-title":"J Pain Res"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib32","first-page":"S64","article-title":"[Interactions between benzodiazepines and opioids]","volume":"154","author":"Megarbane","year":"2003","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.jpet.2026.105002_bib33","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bja.2021.12.001","article-title":"Buprenorphine: a treatment and cause of opioid-induced respiratory depression","volume":"128","author":"Dahan","year":"2022","journal-title":"Br J Anaesth"},{"issue":"7","key":"10.1016\/j.jpet.2026.105002_bib34","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1007\/s00213-023-06390-y","article-title":"Xylazine effects on opioid-induced brain hypoxia","volume":"240","author":"Choi","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"issue":"10","key":"10.1016\/j.jpet.2026.105002_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103711","article-title":"Interactions between cardiorespiratory effects of fentanyl and xylazine and their reversal in male and female Sprague-Dawley rats","volume":"392","author":"Puzovic","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib36","doi-asserted-by":"crossref","first-page":"846","DOI":"10.3390\/ph19060846","article-title":"Does kappa agonism improve reversal of \"tranq-dope\" overdose? Evidence from a rodent model","volume":"19","author":"Voronkov","year":"2026","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jpet.2026.105002_bib37","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-026-07031-w","article-title":"Xylazine exacerbates fentanyl-induced respiratory depression and prevents rescue by naloxone in mice","author":"Watkins","year":"2026","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"10.1016\/j.jpet.2026.105002_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103616","article-title":"Xylazine exacerbates fentanyl-induced respiratory depression and bradycardia","volume":"392","author":"Demery","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.jpet.2026.105002_bib39","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/s41386-023-01782-2","article-title":"Combined treatment with naloxone and the alpha2 adrenoceptor antagonist atipamezole reversed brain hypoxia induced by a fentanyl-xylazine mixture in a rat model","volume":"49","author":"Choi","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpet.2026.105002_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1280289","article-title":"\u201cTranq-dope\u201d overdose and mortality: lethality induced by fentanyl and xylazine","volume":"14","author":"Smith","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2026.105002_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1354722","article-title":"Brain oxygen responses induced by opioids: focus on heroin, fentanyl, and their adulterants","volume":"15","author":"Kiyatkin","year":"2024","journal-title":"Front Psychiatry"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/15563650.2024.2309326","article-title":"Evaluation of the relationship of xylazine and fentanyl blood concentrations among fentanyl-associated fatalities","volume":"62","author":"Hays","year":"2024","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib43","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12954-024-00940-z","article-title":"Reported xylazine exposure highly associated with overdose outcomes in a rapid community assessment among people who inject drugs in Baltimore","volume":"21","author":"German","year":"2024","journal-title":"Harm Reduct J"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/ADM.0000000000001264","article-title":"Xylazine use among people who inject drugs, Philadelphia 2022","volume":"18","author":"Tan","year":"2024","journal-title":"J Addict Med"},{"key":"10.1016\/j.jpet.2026.105002_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.111282","article-title":"Xylazine does not enhance fentanyl reinforcement in rats: a behavioral economic analysis","volume":"258","author":"St. Onge","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"19","key":"10.1016\/j.jpet.2026.105002_bib46","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.3390\/molecules30193890","article-title":"Nitazenes: the emergence of a potent synthetic opioid threat","volume":"30","author":"Pereira","year":"2025","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.jpet.2026.105002_bib47","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s00213-023-06451-2","article-title":"Alkoxy chain length governs the potency of 2-benzylbenzimidazole \u201cnitazene\u201d opioids associated with human overdose","volume":"240","author":"Glatfelter","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jpet.2026.105002_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/adar.2022.10280","article-title":"Interaction with the lipid membrane influences fentanyl pharmacology","volume":"2","author":"Sutcliffe","year":"2022","journal-title":"Adv Drug Alcohol Res"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib49","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s43856-024-00536-5","article-title":"Whole body physiology model to simulate respiratory depression of fentanyl and associated naloxone reversal","volume":"4","author":"Baird","year":"2024","journal-title":"Commun Med"},{"issue":"4","key":"10.1016\/j.jpet.2026.105002_bib50","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2361","article-title":"Alcohol or benzodiazepine co-involvement with opioid overdose deaths in the United States, 1999-2017","volume":"3","author":"Tori","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jpet.2026.105002_bib51","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.resp.2004.02.004","article-title":"GABAA receptors mediate postnatal depression of respiratory frequency by barbiturates","volume":"140","author":"Fregosi","year":"2004","journal-title":"Respir Physiol Neurobiol"},{"issue":"4","key":"10.1016\/j.jpet.2026.105002_bib52","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0091-3057(03)00020-0","article-title":"Effects of NMDA receptor antagonists on opioid-induced respiratory depression and acute antinociception in rats","volume":"74","author":"Hoffmann","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150214","article-title":"Association of opioids and sedatives with increased risk of in-hospital cardiopulmonary arrest from an administrative database","volume":"11","author":"Overdyk","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.jpet.2026.105002_bib54","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s11606-019-05545-y","article-title":"Risk of overdose with exposure to prescription opioids, benzodiazepines, and non-benzodiazepine sedative-hypnotics in adults: a retrospective cohort study","volume":"35","author":"Cho","year":"2020","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib55","doi-asserted-by":"crossref","DOI":"10.1111\/acem.70104","article-title":"Benzodiazepine co-exposure among patients presenting to the emergency department with a confirmed opioid overdose","volume":"33","author":"Hughes","year":"2026","journal-title":"Acad Emerg Med"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib56","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/jcph.6132","article-title":"Time course of reversal of fentanyl-induced respiratory depression in healthy subjects by intramuscular nalmefene and intramuscular and intranasal naloxone","volume":"65","author":"Cipriano","year":"2025","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2026.105002_bib57","first-page":"492","article-title":"Intravenous buprenorphine reversed opioid-induced respiratory depression without precipitating withdrawal in emergency department patients","volume":"87","author":"Spadaro","year":"2026","journal-title":"J Stud Alcohol Drugs"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/135562102200120442","article-title":"In vivo and in vitro potency studies of 6beta-naltrexol, the major human metabolite of naltrexone","volume":"7","author":"Porter","year":"2002","journal-title":"Addict Biol"},{"key":"10.1016\/j.jpet.2026.105002_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2025.174060","article-title":"The novel synthesized naltrexone-related MOR antagonist AT-99 counteracts dopamine releasing and behavioral depressant morphine-induced effects","volume":"255","author":"Mostallino","year":"2025","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib60","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1124\/jpet.120.000387","article-title":"Methocinnamox reverses and prevents fentanyl-induced ventilatory depression in rats","volume":"377","author":"Jimenez","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"issue":"14","key":"10.1016\/j.jpet.2026.105002_bib61","doi-asserted-by":"crossref","first-page":"9466","DOI":"10.1021\/acs.jmedchem.3c00061","article-title":"Structure- activity relationship study of cannabidiol-based analogs as negative allosteric modulators of the \u03bc-opioid receptor","volume":"66","author":"Bosquez-Berger","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.jpet.2026.105002_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121326","article-title":"Modifying naloxone to reverse fentanyl-induced overdose","volume":"611","author":"Voronkov","year":"2022","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.121.001048","article-title":"Pharmacological profiling of antifentanyl monoclonal antibodies in combination with naloxone in pre- and postexposure models of fentanyl toxicity","volume":"381","author":"Baehr","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"10.1016\/j.jpet.2026.105002_bib64","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acschemneuro.3c00455","article-title":"An engineered human-antibody fragment with fentanyl pan-specificity that reverses carfentanil-induced respiratory depression","volume":"14","author":"Eubanks","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"10.1016\/j.jpet.2026.105002_bib65","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3390\/pharmaceutics14112290","article-title":"An immunconjugate vaccine alters distribution and reduces the antinociceptive, behavioral and physiological effects of fentanyl in male and female rats","volume":"14","author":"Haile","year":"2022","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib66","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.118.253674","article-title":"A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats","volume":"368","author":"Raleigh","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jpet.2026.105002_bib67","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chempr.2022.11.019","article-title":"Pillar[6]MaxQ: a potent supramolecular host for in vivo sequestration of methamphetamine and fentanyl","volume":"9","author":"Brockett","year":"2023","journal-title":"Chem"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib68","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.bja.2020.02.019","article-title":"Calabadion 1 selectively reverses respiratory and central nervous system effects of fentanyl in a rat model","volume":"125","author":"Thevathasan","year":"2020","journal-title":"Br J Anaesth"},{"issue":"13","key":"10.1016\/j.jpet.2026.105002_bib69","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1021\/acschemneuro.0c00141","article-title":"Novel oral nanoparticle formulation of sustained release naloxone with mild withdrawal symptoms in mice","volume":"11","author":"Madison","year":"2020","journal-title":"ACS Chem Neurosci"},{"issue":"17","key":"10.1016\/j.jpet.2026.105002_bib70","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1016\/j.bmcl.2009.07.061","article-title":"Human plasma-mediated hypoxic activation of indolequinone-based naloxone pro-drugs","volume":"19","author":"Huang","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.jpet.2026.105002_bib71","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41467-025-55945-4","article-title":"Development and preclinical testing of a naloxone prodrug depot for extended protection against opioid overdose","volume":"16","author":"Aldawod","year":"2025","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.jpet.2026.105002_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103768","article-title":"The effects of buprenorphine on fentanyl-induced respiratory depression in rats","volume":"392","author":"Baehr","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.jpet.2026.105002_bib73","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/s41386-020-0698-8","article-title":"Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys","volume":"45","author":"Maguire","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"8021","key":"10.1016\/j.jpet.2026.105002_bib74","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41586-024-07587-7","article-title":"A \u03bc-opioid receptor modulator that works cooperatively with naloxone","volume":"631","author":"O\u2019Brien","year":"2024","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib75","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2122507","article-title":"Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development","volume":"18","author":"Hicks","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.jpet.2026.105002_bib76","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00213-025-06751-9","article-title":"A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys","volume":"242","author":"Galbo-Thomma","year":"2025","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.jpet.2026.105002_bib77","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40264-020-01020-4","article-title":"Evaluation of opioid overdose reports in patients treated with extended-release naltrexone: postmarketing data from 2006 to 2018","volume":"44","author":"Jain","year":"2021","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.jpet.2026.105002_bib78","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1097\/ALN.0000000000003128","article-title":"Countering opioid-induced respiratory depression in male rats with nicotinic acetylcholine receptor partial agonists varenicline and ABT 594","volume":"132","author":"Ren","year":"2020","journal-title":"Anesthesiology"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib79","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/ALN.0000000000002676","article-title":"Activating \u03b14\u03b22 nicotinic acetylcholine receptors alleviates fentanyl-induced respiratory depression in rats","volume":"130","author":"Ren","year":"2019","journal-title":"Anesthesiology"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib80","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1097\/ALN.0b013e31819faa2a","article-title":"Ampakine CX717 protects against fentanyl-induced respiratory depression and lethal apnea in rats","volume":"110","author":"Ren","year":"2009","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib81","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/clpt.2009.194","article-title":"Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia","volume":"87","author":"Oertel","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib82","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1164\/rccm.201410-1898OC","article-title":"Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats","volume":"191","author":"Ren","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"23","key":"10.1016\/j.jpet.2026.105002_bib83","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.4155\/fmc-2020-0256","article-title":"The impact and mechanism of ampakine CX1739 on protection against respiratory depression in rats","volume":"12","author":"Xiao","year":"2020","journal-title":"Future Med Chem"},{"issue":"12","key":"10.1016\/j.jpet.2026.105002_bib84","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/rccm.200606-778OC","article-title":"Ampakines alleviate respiratory depression in rats","volume":"174","author":"Ren","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib85","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0028-3908(01)00133-2","article-title":"Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546","volume":"41","author":"Nagarajan","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.jpet.2026.105002_bib86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/978-3-319-18440-1_41","article-title":"GAL-021 and GAL-160 are efficacious in rat models of obstructive and central sleep apnea and inhibit BKCa in isolated rat carotid body glomus cells","volume":"860","author":"Dallas","year":"2015","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.jpet.2026.105002_bib87","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/bja\/aeu182","article-title":"GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers","volume":"113","author":"McLeod","year":"2014","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.jpet.2026.105002_bib88","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/bja\/49.3.227","article-title":"Evidence of a role for the peripheral chemoreceptors in the ventilatory response to doxapram in man","volume":"49","author":"Scott","year":"1977","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib89","first-page":"287","article-title":"[The influence of doxapram in human on the respiratory depression by fentanyl (author\u2019s transl)]","volume":"27","author":"Grote","year":"1978","journal-title":"Anaesthesist"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0014-2999(80)90155-7","article-title":"Long-lasting hyperventilation induced by almitrine: evidence for a specific effect on carotid and thoracic chemoreceptors","volume":"61","author":"Laubie","year":"1980","journal-title":"Eur J Pharmacol"},{"issue":"5630","key":"10.1016\/j.jpet.2026.105002_bib91","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1126\/science.1084674","article-title":"5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia","volume":"301","author":"Manzke","year":"2003","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib92","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1161\/HYPERTENSIONAHA.107.091033","article-title":"5-Hydroxytryptamine 1A\/7 and 4alpha receptors differentially prevent opioid-induced inhibition of brain stem cardiorespiratory function","volume":"50","author":"Wang","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.jpet.2026.105002_bib93","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0022-3565(24)35342-X","article-title":"Reversal of morphine-induced apnea in the anesthetized rat by drugs that activate 5-hydroxytryptamine(1A) receptors","volume":"292","author":"Sahibzada","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.jpet.2026.105002_bib94","article-title":"ENA-001 reverses xylazine\/fentanyl combination-induced respiratory depression in rats: a qualitative pilot study","volume":"16","author":"Miller","year":"2024","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.jpet.2026.105002_bib95","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3390\/ph17070866","article-title":"Nalbuphine potentiates reversal of fentanyl overdose by naloxone","volume":"17","author":"Cernea","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.jpet.2026.105002_bib96","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70007","article-title":"Could flumazenil be used pre-hospital by intramuscular injection for coma due to mixed drug overdose not responding to naloxone?: a systematic review of the evidence","volume":"136","author":"Farcas","year":"2025","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jpet.2026.105002_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.forsciint.2023.111777","article-title":"Fentanyl concentrations in ligated femoral blood in the presence and absence of NPS benzodiazepine drugs. A review of over 1250 benzo-dope \/ fentanyl toxicity cases in Alberta, Canada","volume":"350","author":"Chatterton","year":"2023","journal-title":"Forensic Sci Int"},{"issue":"5","key":"10.1016\/j.jpet.2026.105002_bib98","first-page":"271","article-title":"[The effect of flumazenil on alfentanyl-induced respiratory depression]","volume":"40","author":"Behne","year":"1991","journal-title":"Anaesthesist"},{"issue":"7","key":"10.1016\/j.jpet.2026.105002_bib99","first-page":"391","article-title":"[The action of flumazenil in combination with fentanyl on spontaneous respiration]","volume":"41","author":"Tolksdorf","year":"1992","journal-title":"Anaesthesist"},{"issue":"7","key":"10.1016\/j.jpet.2026.105002_bib100","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1152\/japplphysiol.00752.2012","article-title":"Respiratory depression in rats induced by alcohol and barbiturate and rescue by ampakine CX717","volume":"113","author":"Ren","year":"2012","journal-title":"J Appl Physiol"},{"issue":"6","key":"10.1016\/j.jpet.2026.105002_bib101","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/ALN.0b013e318291079c","article-title":"Coadministration of the AMPAKINE CX717 with propofol reduces respiratory depression and fatal apneas","volume":"118","author":"Ren","year":"2013","journal-title":"Anesthesiology"},{"issue":"5","key":"10.1016\/j.jpet.2026.105002_bib102","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1152\/jappl.1982.52.5.1261","article-title":"Stimulation of carotid chemoreceptors and ventilation by doxapram in the cat","volume":"52","author":"Nishino","year":"1982","journal-title":"J Appl Physiol"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526012024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:45:03Z","timestamp":1790700303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526012024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":101,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0022356526012024"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105002","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dynamic mechanistic dominance in fentanyl and polysubstance overdose: Implications for next-generation reversal","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.105002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105002"}}